Literature DB >> 28884609

Impact of Classical Risk Factors for Arterial or Venous Thrombosis in Patients With Antiphospholipid Syndrome.

Daniel Navarro-Carpentieri1, Maria Del Carmen Castillo-Hernandez2, Karim Majluf-Cruz1, Guillermo Espejo-Godinez1, Paola Carmona-Olvera1, Manuel Moreno-Hernandez1, Yolanda Lugo-García3, Jesús Hernandez-Juarez1, Luis Loarca-Piña4, Irma Isordia-Salas1, Abraham Majluf-Cruz1.   

Abstract

There are classical risk factors associated with arterial thrombosis (AT) or venous thromboembolic disease (VTD). However, less is known about these risk factors and AT or VTD episodes in patients with antiphospholipid syndrome (APS). Our aim was to elucidate whether APS-related thrombotic episodes are associated with the same risk factors as the non-APS population. We gathered demographics, medical history, complications, and causes of death associated with the risk factors for AT or VTD in patients with APS. We analyzed 677 thrombotic events in 386 patients. Type 2 diabetes mellitus and grade 3 obesity were associated with VTD instead of AT. There were no significant differences between the groups for almost all laboratory tests analyzed, although lupus anticoagulant was significantly higher in the VTD group. We suggest that thrombosis in APS is due to the APS itself and that the risks factors for AT or VTD do not have a main role. Our findings may have an ethnical background. Therefore, it may be difficult to elaborate predictive thrombotic clinical scores applicable to patients with different ethnical background.

Entities:  

Keywords:  antiphospholipid syndrome; antiphospolipid antibodies; arterial thrombosis; thromboembolic risk factors; venous thrombosis

Mesh:

Substances:

Year:  2017        PMID: 28884609      PMCID: PMC6714872          DOI: 10.1177/1076029617727859

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  29 in total

Review 1.  Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients.

Authors:  R Cervera; R A Asherson; M L Acevedo; J A Gómez-Puerta; G Espinosa; G De La Red; V Gil; M Ramos-Casals; M García-Carrasco; M Ingelmo; J Font
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

Review 2.  The catastrophic antiphospholipid syndrome.

Authors:  R A Asherson
Journal:  J Rheumatol       Date:  1992-04       Impact factor: 4.666

3.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).

Authors:  S Miyakis; M D Lockshin; T Atsumi; D W Branch; R L Brey; R Cervera; R H W M Derksen; P G DE Groot; T Koike; P L Meroni; G Reber; Y Shoenfeld; A Tincani; P G Vlachoyiannopoulos; S A Krilis
Journal:  J Thromb Haemost       Date:  2006-02       Impact factor: 5.824

Review 4.  Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients.

Authors:  José A Gómez-Puerta; Ricard Cervera; Gerard Espinosa; Sira Aguiló; Silvia Bucciarelli; Manuel Ramos-Casals; Miguel Ingelmo; Ronald A Asherson; Josep Font
Journal:  Semin Arthritis Rheum       Date:  2006-04       Impact factor: 5.532

Review 5.  Antiphospholipid syndrome: pathogenic mechanisms.

Authors:  Gerard Espinosa; Ricard Cervera; Josep Font; Yehuda Shoenfeld
Journal:  Autoimmun Rev       Date:  2003-03       Impact factor: 9.754

6.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

Review 7.  Resistance to annexin A5 anticoagulant activity: a thrombogenic mechanism for the antiphospholipid syndrome.

Authors:  J H Rand; X X Wu; A S Quinn; D J Taatjes
Journal:  Lupus       Date:  2008-10       Impact factor: 2.911

Review 8.  Mechanisms of venous thrombosis and resolution.

Authors:  Thomas W Wakefield; Daniel D Myers; Peter K Henke
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-03       Impact factor: 8.311

Review 9.  The prevalence and clinical significance of inherited thrombophilic risk factors in patients with antiphospholipid syndrome.

Authors:  Reyhan Diz-Kucukkaya; Veysel Sabri Hancer; Bahar Artim-Esen; Yuksel Pekcelen; Murat Inanc
Journal:  J Thromb Thrombolysis       Date:  2010-04       Impact factor: 2.300

Review 10.  Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms.

Authors:  Silvia S Pierangeli; Pojen P Chen; Elena Raschi; Silvia Scurati; Claudia Grossi; Maria Orietta Borghi; Ivan Palomo; E Nigel Harris; Pier Luigi Meroni
Journal:  Semin Thromb Hemost       Date:  2008-04       Impact factor: 4.180

View more
  2 in total

1.  Dissimilarity in the Frequency of Venous Thromboembolism Risk Factors among Studies, a Commentary.

Authors:  Meghdad Sedaghat; Mahsa Soltani; Mehrdad Solooki
Journal:  Emerg (Tehran)       Date:  2018-01-18

2.  Differential diagnosis and clinical management of isolated prolonged activated partial thromboplastin time in a patient with Hashimoto thyroiditis-associated thyroid cancer: A case report.

Authors:  Yuhong Zhong; Biyong Yan; Zhongqi Yu; Lin Wang
Journal:  Medicine (Baltimore)       Date:  2021-07-09       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.